TRENTAL TABLET (EXTENDED-RELEASE)

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

PENTOXIFYLLINE

Disponible desde:

SANOFI-AVENTIS CANADA INC

Código ATC:

C04AD03

Designación común internacional (DCI):

PENTOXIFYLLINE

Dosis:

400MG

formulario farmacéutico:

TABLET (EXTENDED-RELEASE)

Composición:

PENTOXIFYLLINE 400MG

Vía de administración:

ORAL

Unidades en paquete:

60

tipo de receta:

Prescription

Área terapéutica:

HEMORRHEOLOGIC AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0115837001; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2013-03-01

Ficha técnica

_ _
_ _
_Page 1 of 21_
PRODUCT MONOGRAPH
P
r
TRENTAL
®
(pentoxifylline sustained release tablets, 400 mg Mfr. Std.)
Vasoactive agent
ATC Code : C04AD03
sanofi-aventis Canada Inc.
DATE OF REVISION:
2150 St. Elzear Blvd. West
MARCH 30, 2011
Laval, Quebec H7L 4A8
SUBMISSION CONTROL NO.: 142355
s-a Version dated
_ _
_ _
_Page 2 of 21_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................. 3
SUMMARY
PRODUCT
INFORMATION........................................................ 3
INDICATIONS
AND
CLINICAL
USE ............................................................. 3
CONTRAINDICATIONS
..................................................................................
3
WARNINGS
AND
PRECAUTIONS
................................................................. 4
ADVERSE
REACTIONS...................................................................................
5
DRUG
INTERACTIONS
...................................................................................
7
DOSAGE
AND
ADMINISTRATION
............................................................... 8
OVERDOSAGE
.................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY.............................................. 9
STORAGE
AND
STABILITY
...........................................................................
9
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ............................. 10
PART II: SCIENTIFIC INFORMATION
....................................................... 11
PHARMACEUTICAL
INFORMATION.........................................................
11
DETAILED
PHARMACOLOGY
....................................................................
12
TOXICOLOGY
................................................................................................
14
REFERENCES
.................................................................................................
18
PART III: CONSUMER
INFORMATION...................................................... 20